PAVM - PAVmed Primed To Deliver Significant Value For Shareholders
- PAVmed has significant room to grow in the next year with their extensive pipeline for a range of clinical conditions, with an addressable market of over $3 billion.
- The company has recognizable and successful management led by Lishan Aklog, with the recent addition of Stanley Lapidus as a special advisor, the founder of Exact Sciences.
- Based on current valuations of ~$300M, I believe with recent events and the pipeline, it has room to provide shareholders with a significant ROI.
- Recent news of a spin-off of their Lucid Diagnostics subsidiary should provide PAVmed more room to expand their other lucrative products.
For further details see:
PAVmed Primed To Deliver Significant Value For Shareholders